Examining differences in how prostate tumor lesions are identified using MRI
Inter-observer Variability in the Segmentation of Prostate Tumour Lesions Using Multiparametric MRI
This study looks at how different doctors identify prostate tumors using MRI to see if improving this process can help make radiation treatment more accurate for patients with prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Trial ID | NCT05996289 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the variability among different operators in the segmentation of prostate tumor lesions using multiparametric MRI. It aims to address the challenges in accurately identifying and delineating the dominant lesion, which is crucial for effective radiotherapy planning. By analyzing a retrospective cohort from the Finistère region, the study will explore factors influencing contour variability, the impact of this variability on dosimetry, and the potential for automatic segmentation techniques. The findings could enhance the precision of radiotherapy for prostate cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult males aged 18 and older with histologically confirmed localized prostate cancer who have undergone multiparametric MRI.
Not a fit: Patients with a history of prostate cancer, prior treatments, or those without an identifiable target lesion on MRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved accuracy in tumor delineation, ultimately enhancing treatment outcomes for prostate cancer patients.
How similar studies have performed: While the study addresses a known issue in radiotherapy, the specific focus on inter-operator variability in MRI segmentation is less commonly explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically proven localized prostatic neoplasia on trans-rectal biopsies. * Multiparametric prostate MRI performed prior to prostate biopsies. * No opposition expressed * Patient affiliated to a social security scheme Exclusion Criteria: * History of surgery, prostatic irradiation or hormonal treatment prior to diagnosis. * History of prostate cancer * No identifiable target lesion on mpMRI (\<PIRADS 3) * Opposition formulated * Patient under legal protection (guardianship, curatorship, etc.)
Where this trial is running
Brest
- Chu Brest — Brest, France (Recruiting)
Study contacts
- Principal investigator: Vincent Bourbonne, MD, PhD — Radiation Oncology Department, Brest University Hospital
- Study coordinator: Vincent BOURBONNE, MD, PhD
- Email: vincent.bourbonne@chu-brest.fr
- Phone: +33298223398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.